Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

bozepinib

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Enhancement of Tumor Cell Death by Combining gef Gene Mediated Therapy and New 1,4-Benzoxazepin-2,6-Dichloropurine Derivatives in Breast Cancer Cells
New treatment modalities are urgently needed to better manage advanced breast cancer. Combination therapies are usually more… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2017
2017
1-(Benzenesulfonyl)-1,5-dihydro-4,1-benzoxazepine as a new scaffold for the design of antitumor compounds.
AIM Bozepinib is a potent and selective anticancer compound which chemical structure is made up of a benzofused seven-membered… Expand
2014
2014
HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib
Identification of novel anticancer drugs presenting more than one molecular target and efficacy against cancer stem-like cells… Expand
2013
2013
Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFNα triggering apoptosis, autophagy and senescence
Bozepinib [(RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-9H-purine] is a potent… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE